mely encouraging results from the interim analysis of the phase I/II nivolumab Darifenacin trial (CA209-040 trial) evaluating the efficacy of nivolumab in patients with hepatocellular carcinoma (HCC) were reported at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Darifenacin held in Chicago from May 29 to June 2 Darifenacin Darifenacin 2015 [1]. HCC… Continue reading mely encouraging results from the interim analysis of the phase I/II